Press releases
- RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
- RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
- RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
- RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price
- RedHill Announces New USPTO Patent Covering Talicia® Through 2034
- RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
More ▼
Key statistics
On Friday, Redhill Biopharma Ltd (2RH0:BER) closed at 0.4155, 45.28% above the 52 week low of 0.286 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.4235 |
---|---|
High | 0.4355 |
Low | 0.4125 |
Bid | 0.3885 |
Offer | 0.4485 |
Previous close | 0.4195 |
Average volume | 5.63k |
---|---|
Shares outstanding | 31.87m |
Free float | 31.67m |
P/E (TTM) | 0.1241 |
Market cap | 14.60m USD |
EPS (TTM) | 3.69 USD |
Data delayed at least 15 minutes, as of May 31 2024 19:30 BST.
More ▼